Merdury BiopharmaceuticalCorporation (Merdury) (Taipei Exchange Stock Code: 6932) announced today thatit has signed a Memorandum of Understanding (MOU) with Health2Sync, Asia'slargest chronic disease management platform. This collaboration aims to enhancethe clinical evidence supporting the superior pharmacokinetic profile of oralsemaglutide when delivered via Merdury's StackDose™ technology. As a GLP-1agonist, semaglutide has demonstrated remarkable efficacy in treating Type 2 diabetesand obesity. Its exceptional weight reduction capabilities led to FDA approvalfor weight management in the US in 2021, and it is rapidly gaining popularityin the US and around the world.
In the pre-clinical studies, Merdury observed encouragingresults indicating that the innovative formulation, utilizing its StackDose™technology platform, significantly enhances semaglutide's absorption andbioavailability. This enhancement leads to prolonged blood concentration andextended duration of action compared to existing oral semaglutide formulations onthe market. With the ambition of bringing more effective treatments to patientsworldwide, Merdury has filed patent applications for its technology in multiplecountries.
"We are excited to partner with Health2Sync inclinical trials to demonstrate StackDose’s ability to enhance the area underthe [pharmacokinetic] curve (AUC)," said Elton Liang, CEO of MerduryBiopharmaceutical Corporation. "Health2Sync's established presence androbust platform in Taiwan will be instrumental in streamlining clinical trialsand ultimately, bringing our innovative therapies to patients worldwide."
Compared to existing options, Merdury's oral tablets increasesthe total drug concentration in the blood by 1.5 times (AUC0-∞) and reducesthe time to peak blood concentration (Tmax) by 43%. This translatesto potentially faster efficacy for patients. To further validate thesepromising results, Health2Sync will leverage its cloud-based care platform and patientapp to integrate users' continuous glucose monitoring data for the next phaseof clinical trials. This partnership aims to demonstrate the highestlevels of quality and efficacy in the clinical trial results of StackDose™platform, supporting licensing discussions with pharmaceutical companies withoral GLP-1 drugs in their portfolios.
“We're thrilled to partner with Merdury and leverageHealth2Sync's platform to advance their innovative drug delivery technology,”said Ed Deng, Co-founder and CEO of Health2Sync. “This collaborationunderscores our commitment to empowering life sciences companies with the toolsthey need to accelerate clinical trials and deliver life-changing solutions topatients struggling with glucose control or weight management.”
Health2Synchas partnered with the world's top life sciences companies active in metabolicdisease, such as Abbott, AstraZeneca, Novo Nordisk and Sanofi, to promotedigital diabetes solutions. The key markets cover Taiwan, Japan, South Korea, Singapore,Egypt, Australia, and other regions. With the Health2Sync app, users can nowview their daily glucose patterns, record their diet and exercise diaries, andadjust the lifestyle habits with the assistance of healthcare professionals andover 80 integrations with smart devices.
About Health2Sync
Establishedin 2013 in Taiwan, Health2Sync made its footprints in Japan in 2018, generatingnearly half of its revenue from overseas operations since then. Empoweringusers and healthcare professionals to effectively manage chronic conditionsthrough early intervention will ultimately alleviate the financial burden onnational healthcare systems. Health2Sync's insulin dose titration software,Insultrate, received Taiwan FDA approval as a Class II medical device inOctober 2023, becoming the first-ever digital therapeutic approved in Taiwan.This algorithmic product was recognized with the "18th National InnovationAward - Enterprise Innovation" award, while Health2Sync was furtherhonored with the "NEXT BIG Startup" title by the National DevelopmentCouncil in the next year. As of June 2024, Health2Sync has over 1.3 millionusers worldwide.
Formore information, visit http://www.health2sync.com
About Merdury Biopharmaceutical Corporation*:
Merdury Biopharmaceutical Corporation* was founded in July 2019, focuses on the development of medications for medical gaps. Merdury Biopharmaceutical Corporation*has developed “StackDose™ new drug technology development platform” that the new dosage tablets can be controlled-dissolved and absorbed at the targeted site by using a 3D powder-printing pharmaceutical manufacturing process combined with a patented pharmaceutical binding formulation, in addition to increasing the bioavailability of active pharmaceutical ingredients (API) to achieve optimal efficacy, allowing for lower drug dosage and less side effects. The company is listed on the Emerging Stock Exchange on December 23, 2022
Moreinformation: https://www.merdury.com/.
Disclaimers:
The documents and information released at the same time include forecast narratives. All statements regarding Merdury Biopharmaceutical Corporation*(hereinafter referred to as the “Company”)'s future operations, probable events, and prospects (including, but not limited to, forecasts, goals, estimates and operating plans), other than those that relate to facts that have already occurred, are statements of a prospective nature. Forecasts are subject to various factors and uncertainties that may cause them to differ materially from the actual situation. These factors include, but are not limited to, price fluctuations, actual demand, changes in foreign exchange rates, market share, market competition, changes in legal, financial, and regulatory frameworks, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the Company's control. These forward-looking statements are based on current projections and evaluations, and the Company is not responsible for future updates.
